$CRSP
CRISPR Therapeutics AG

2016 Q3 Form 10-Q Financial Statement

#000119312516774104 Filed on November 22, 2016

View on sec.gov

Income Statement

Concept 2016 Q3 2015 Q4 2015 Q3
Revenue $1.549M $247.0K $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.100M $6.200M $2.500M
YoY Change 64.0%
% of Gross Profit
Research & Development $12.05M $6.200M $3.749M
YoY Change 221.47%
% of Gross Profit
Depreciation & Amortization $200.0K $60.00K $27.00K
YoY Change 640.74%
% of Gross Profit
Operating Expenses $16.16M $12.41M $6.202M
YoY Change 160.54%
Operating Profit -$14.61M -$12.17M -$6.202M
YoY Change 135.57%
Interest Expense -$1.000K -$100.0K -$8.000K
YoY Change -87.5%
% of Operating Profit
Other Income/Expense, Net -$76.00K $0.00 $1.000K
YoY Change -7700.0%
Pretax Income -$14.69M -$12.20M -$6.201M
YoY Change 136.83%
Income Tax $8.000K $100.0K $153.0K
% Of Pretax Income
Net Earnings -$14.68M -$12.27M -$6.353M
YoY Change 131.07%
Net Earnings / Revenue -947.71% -4967.61%
Basic Earnings Per Share -$2.77
Diluted Earnings Per Share -$2.77 -$309.8K -$161.2K
COMMON SHARES
Basic Shares Outstanding 5.292M
Diluted Shares Outstanding 5.292M

Balance Sheet

Concept 2016 Q3 2015 Q4 2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $228.6M $156.0M
YoY Change
Cash & Equivalents $228.6M $156.0M $49.05M
Short-Term Investments
Other Short-Term Assets $900.0K $500.0K
YoY Change
Inventory
Prepaid Expenses
Receivables $2.092M $339.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $231.7M $156.8M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $3.862M $1.328M
YoY Change
Goodwill
YoY Change
Intangibles $413.0K $454.0K
YoY Change
Long-Term Investments $35.69M $0.00
YoY Change
Other Assets $3.888M $101.0K
YoY Change
Total Long-Term Assets $47.00M $2.583M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $231.7M $156.8M
Total Long-Term Assets $47.00M $2.583M
Total Assets $278.7M $159.4M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.943M $1.584M
YoY Change
Accrued Expenses $12.40M $8.430M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $78.10M $10.16M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $38.30M
YoY Change
Other Long-Term Liabilities $574.0K $281.0K
YoY Change
Total Long-Term Liabilities $574.0K $281.0K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $78.10M $10.16M
Total Long-Term Liabilities $574.0K $281.0K
Total Liabilities $155.6M $124.0M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$74.18M -$33.91M
YoY Change
Common Stock $11.73M $4.817M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $0.00 $0.00
YoY Change
Treasury Stock Shares 274.2K shares $0.00
Shareholders Equity -$62.48M -$29.10M
YoY Change
Total Liabilities & Shareholders Equity $278.7M $159.4M
YoY Change

Cashflow Statement

Concept 2016 Q3 2015 Q4 2015 Q3
OPERATING ACTIVITIES
Net Income -$14.68M -$12.27M -$6.353M
YoY Change 131.07%
Depreciation, Depletion And Amortization $200.0K $60.00K $27.00K
YoY Change 640.74%
Cash From Operating Activities -$12.27M $69.01M -$5.320M
YoY Change 130.64%
INVESTING ACTIVITIES
Capital Expenditures -$1.510M -$500.0K -$550.0K
YoY Change 174.55%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change
Cash From Investing Activities -$1.510M -$500.0K -$550.0K
YoY Change 174.55%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -4.480M 38.48M 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -12.27M 69.01M -5.320M
Cash From Investing Activities -1.510M -500.0K -550.0K
Cash From Financing Activities -4.480M 38.48M 0.000
Net Change In Cash -18.26M 107.0M -5.870M
YoY Change 211.07%
FREE CASH FLOW
Cash From Operating Activities -$12.27M $69.01M -$5.320M
Capital Expenditures -$1.510M -$500.0K -$550.0K
Free Cash Flow -$10.76M $69.51M -$4.770M
YoY Change 125.58%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49049000
CY2016Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1987000
CY2016Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.03
CY2016Q3 us-gaap Cash
Cash
228613000
CY2016Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
544000
CY2016Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5307845 shares
CY2016Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5662126 shares
CY2016Q3 us-gaap Assets
Assets
278653000
CY2016Q3 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
459000
CY2016Q3 us-gaap Assets Current
AssetsCurrent
231651000
CY2016Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
5662126 shares
CY2016Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
11553000
CY2016Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.03
CY2016Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
39808801 shares
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
228613000
CY2016Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2092000
CY2016Q3 us-gaap Common Stock Value
CommonStockValue
174000
CY2016Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
76949000
CY2016Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
38453593 shares
CY2016Q3 us-gaap Equity Method Investments
EquityMethodInvestments
35686000
CY2016Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1943000
CY2016Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
63608000
CY2016Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1971000
CY2016Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-26000
CY2015Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
0
CY2015Q4 us-gaap Assets Current
AssetsCurrent
156840000
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
5528079 shares
CY2016Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12402000
CY2016Q3 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
0
CY2016Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
413000
CY2016Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
62000
CY2016Q3 us-gaap Liabilities
Liabilities
155620000
CY2016Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
278653000
CY2016Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
574000
CY2016Q3 us-gaap Liabilities Current
LiabilitiesCurrent
78097000
CY2016Q3 us-gaap Minority Interest
MinorityInterest
-51000
CY2016Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
172000
CY2016Q3 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures Fair Value Disclosure
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure
91200000
CY2016Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3888000
CY2016Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3862000
CY2016Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4406000
CY2016Q3 us-gaap Stockholders Equity
StockholdersEquity
-62481000
CY2016Q3 us-gaap Taxes Payable Current
TaxesPayableCurrent
82000
CY2016Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-62532000
CY2016Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-74182000
CY2016Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
274184 shares
CY2016Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
946000
CY2016Q3 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.03
CY2016Q3 us-gaap Treasury Stock Value
TreasuryStockValue
0
CY2016Q3 us-gaap Treasury Stock Value
TreasuryStockValue
0
CY2016Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
27135884 shares
CY2016Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
3153000
CY2016Q3 crspr Number Of Expiring Leases
NumberOfExpiringLeases
2 Lease
CY2016Q3 crspr Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1752000
CY2016Q3 crspr Accrued License Fees Current
AccruedLicenseFeesCurrent
281000
CY2016Q3 crspr Common Stock Conditional Capital
CommonStockConditionalCapital
38453593 shares
CY2016Q3 crspr Accrued Intellectual Property Costs Current
AccruedIntellectualPropertyCostsCurrent
4232000
CY2016Q3 crspr Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Unvested Restricted Share Award Not Outstanding
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsUnvestedRestrictedShareAwardNotOutstanding
97744 shares
CY2016Q3 crspr Accrued Advances Liability
AccruedAdvancesLiability
2007000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
945000
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
773000
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.03
CY2015Q4 us-gaap Cash
Cash
155961000
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
72000
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5528079 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5528079 shares
CY2015Q4 us-gaap Assets
Assets
159423000
dei Document Type
DocumentType
10-Q
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1400000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
-29097000
CY2015Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
81000
CY2015Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-29124000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-33906000
CY2015Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
0 shares
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
540000
CY2015Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.03
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
4636000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
155961000
CY2015Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
339000
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
181000
CY2015Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
75090000
CY2015Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
2444364 shares
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1584000
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2412000
CY2015Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
38336000
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-8000
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8430000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
8600000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
1465000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
1422000
CY2015Q4 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
97000
CY2015Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
454000
CY2015Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
60000
CY2015Q4 us-gaap Liabilities
Liabilities
124026000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
159423000
CY2015Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
445000
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10155000
CY2015Q4 us-gaap Minority Interest
MinorityInterest
-27000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
1700000
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
688000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
1291000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
1381000
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
101000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1341000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1328000
CY2015Q4 us-gaap Treasury Stock Value
TreasuryStockValue
0
CY2015Q4 us-gaap Treasury Stock Value
TreasuryStockValue
0
CY2015Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
18837024 shares
CY2015Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
700000
CY2015Q4 crspr Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
910000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
513000
us-gaap Operating Income Loss
OperatingIncomeLoss
-13563000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
58251000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2504000
us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
370000
us-gaap Participating Securities Distributed And Undistributed Earnings Loss Diluted
ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-63000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-9576000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
651000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
551000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6399000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1703403 shares
us-gaap Profit Loss
ProfitLoss
-13542000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.01
CY2015Q4 crspr Accrued License Fees Current
AccruedLicenseFeesCurrent
1055000
CY2015Q4 crspr Common Stock Conditional Capital
CommonStockConditionalCapital
2444364 shares
CY2015Q4 crspr Accrued Intellectual Property Costs Current
AccruedIntellectualPropertyCostsCurrent
2592000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21002491000 shares
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
48104000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.72
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2508000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
32000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7164000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
80000
us-gaap Depreciation
Depreciation
27000.0
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
68000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13544000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
99000
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.005 pure
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-9000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
700000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-42000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-33000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
49000
us-gaap Operating Expenses
OperatingExpenses
13563000
us-gaap Net Income Loss
NetIncomeLoss
-13233000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-309000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13605000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-651000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2000
us-gaap Share Based Compensation
ShareBasedCompensation
2508000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4872048 shares
dei Entity Registrant Name
EntityRegistrantName
CRISPR THERAPEUTICS AG
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
31327572000 shares
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y3M18D
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-8051000
us-gaap Revenues
Revenues
2820000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1400000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2604000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-141000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
11000
dei Entity Central Index Key
EntityCentralIndexKey
0001674416
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2013-10-28
dei Document Period End Date
DocumentPeriodEndDate
2016-09-30
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
72652000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-7.43
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6816000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
246000
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18974000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-20000
us-gaap Depreciation
Depreciation
500000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
513000
dei Entity Incorporation State Country Name
EntityIncorporationStateCountryName
Basel, Switzerland
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-40318000
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
7000
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.002 pure
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
91454000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-28000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3275000
us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
1810000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1220000
us-gaap Participating Securities Distributed And Undistributed Earnings Loss Diluted
ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
11482000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
694000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
84000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-35894000
us-gaap Lease Expiration Date1
LeaseExpirationDate1
2016-09-30
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2788000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
2453000
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
100000
us-gaap Operating Expenses
OperatingExpenses
45640000
us-gaap Net Income Loss
NetIncomeLoss
-40276000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-24000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-40216000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
17112000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-18000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1753000
us-gaap Operating Income Loss
OperatingIncomeLoss
-42820000
us-gaap Paid In Kind Interest
PaidInKindInterest
8050000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
35000000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-686000
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6202000
CY2015Q3 us-gaap Participating Securities Distributed And Undistributed Earnings Loss Diluted
ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
16000
us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
3.33 pure
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
61929000
us-gaap Research And Development Arrangement Contract To Perform For Others Description And Terms
ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms
The research collaboration will end on the earlier of the date on which Vertex has exercised six options to obtain exclusive/co-exclusive licenses with respect to a collaboration target, or the fourth anniversary of the effective date of the agreement. The research term may be extended as mutually agreed by the parties up to nine additional months to complete any research activities under the approved research plan that are incomplete on the fourth anniversary of the effective date.
dei Trading Symbol
TradingSymbol
crspr
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26666000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2677000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1847506 shares
us-gaap Profit Loss
ProfitLoss
-40300000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.68
us-gaap Share Based Compensation
ShareBasedCompensation
6816000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5422617 shares
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
385000
us-gaap Stockholders Equity Note Stock Split
StockholdersEquityNoteStockSplit
3 1/3-for-one
crspr Increase Decrease In Deferred Rent Payable
IncreaseDecreaseInDeferredRentPayable
196000
crspr Proceeds From Contribution Of Intellectual Property To Equity Method Investee
ProceedsFromContributionOfIntellectualPropertyToEquityMethodInvestee
20000000
crspr Noncash Contribution Of Intellectual Property To Equity Method Investee
NoncashContributionOfIntellectualPropertyToEquityMethodInvestee
36372000
crspr Joint Venture Agreement Date
JointVentureAgreementDate
2015-12-19
crspr Operating Lease Number Of Leases
OperatingLeaseNumberOfLeases
4 Lease
crspr Maximum Obligation To Make Advance Payments Under The Shareholders Agreement
MaximumObligationToMakeAdvancePaymentsUnderTheShareholdersAgreement
200000
crspr Costs For Proposed Public Offering In Accounts Payable And Accrued Expenses
CostsForProposedPublicOfferingInAccountsPayableAndAccruedExpenses
825000
CY2015 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y3M18D
CY2015Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21002491000 shares
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.15
CY2015Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1029000
CY2015Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2453000
CY2015Q3 us-gaap Depreciation
Depreciation
27000.0
CY2015Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6358000
CY2015Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-8000
CY2015Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
400000
CY2015Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1000
CY2015Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
9000
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
6202000
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-6353000
CY2015Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1000
CY2015Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6201000
CY2015Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-4000
CY2015Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
153000
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3749000
CY2015Q3 us-gaap Profit Loss
ProfitLoss
-6354000
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5528079 shares
CY2016Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
31327572000 shares
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.77
CY2016Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2293000
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4107000
CY2016Q3 us-gaap Depreciation
Depreciation
200000
CY2016Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14695000
CY2016Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1000
CY2016Q3 us-gaap Revenues
Revenues
1549000
CY2016Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
500000
CY2016Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-76000
CY2016Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-75000
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
16159000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-14680000
CY2016Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-14000
CY2016Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14686000
CY2016Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1000
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-14610000
CY2016Q3 us-gaap Participating Securities Distributed And Undistributed Earnings Loss Diluted
ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted
0
CY2016Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
8000
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12052000
CY2016Q3 us-gaap Profit Loss
ProfitLoss
-14694000
CY2016Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5292348 shares
CY2016Q3 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
385000

Files In Submission

Name View Source Status
0001193125-16-774104-index-headers.html Edgar Link pending
0001193125-16-774104-index.html Edgar Link pending
0001193125-16-774104.txt Edgar Link pending
0001193125-16-774104-xbrl.zip Edgar Link pending
crspr-20160930.xml Edgar Link completed
crspr-20160930.xsd Edgar Link pending
crspr-20160930_cal.xml Edgar Link unprocessable
crspr-20160930_def.xml Edgar Link unprocessable
crspr-20160930_lab.xml Edgar Link unprocessable
crspr-20160930_pre.xml Edgar Link unprocessable
d241101d10q.htm Edgar Link pending
d241101dex311.htm Edgar Link pending
d241101dex312.htm Edgar Link pending
d241101dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending